ABSENCE OF POINT MUTATIONS IN A FUNCTIONALLY IMPORTANT PART OF THE EXTRACELLULAR DOMAIN OF THE C-KIT PROTOONCOGENE IN A SERIES OF PATIENTS WITH ACUTE MYELOID-LEUKEMIA (AML)

被引:0
|
作者
ARLAND, M [1 ]
FIEDLER, W [1 ]
SAMALECOS, A [1 ]
HOSSFELD, DK [1 ]
机构
[1] UNIV HAMBURG,HOSP EPPENDORF,DEPT HEMATOL ONCOL,D-20246 HAMBURG,GERMANY
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The proto-oncogenes c-fms and c-kit belong to a family of growth factor receptors possessing protein kinase activity. It has been shown that transfection of a c-fms gene carrying a point mutation at codon 301, leads to a ligand-independent transformation of mouse NIH3T3 cells. In human acute myeloid leukemia (AML), point mutations at codon 301 of the c-fms gene have been observed implying an important role in the transformation process. The possibility of a point mutation of the c-kit proto-oncogene was investigated. We sequenced a segment of the c-kit proto-oncogene coding for a part of the extracellular domain. This segment was 40.7% homologous to the c-fms region encompassing codon 301. c-DNA was prepared from peripheral blood or bone marrow cells from 25 patients with AML, from four patients with myelodysplastic syndrome (MDS) and from three human myeloid cell lines. The region of interest was amplified with two rounds of polymerase chain reactions (PCR) with nested primers and directly sequenced. No point mutations were found in the investigated samples. Thus, point mutations in this segment of the c-kit gene do not seem to play an important role in the transformation process of human acute leukemia.
引用
收藏
页码:498 / 501
页数:4
相关论文
共 50 条
  • [21] A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed C-Kit Positive Acute Myeloid Leukemia (AML)
    Advani, Anjali
    Cooper, Brenda
    Sowunmi, Olumuyiwa
    Elson, Paul
    Ali-Osman, Francis
    Park, Jino
    Rao, Arati
    Rizzieri, David A.
    Wang, Eunice S.
    Cotta, Claudiu
    Sekeres, Mikkael A.
    Kalaycio, Matt
    Sobecks, Ronald
    Rouphail, Basel
    Maciejewski, Jaroslaw P.
    Davis, Randall
    Bailey, Laura
    Foster, Bethany
    Rush, Mary Lynn
    Adams, Donna
    Tse, William
    BLOOD, 2012, 120 (21)
  • [22] A phase 1 trial of imatinib mesylate in combination with daunorubicin and cytarabine for patients for c-kit positive relapsed acute myeloid leukemia (AML)
    Advani, Anjali S.
    Sobecks, Ronald
    Sekeres, Mikkael A.
    Copelan, Ed
    Bates, Jennifer
    Tripp, Barbara
    Salvado, August
    Kalaycio, Matt
    BLOOD, 2007, 110 (11) : 276A - 276A
  • [23] The efficacy and safety of imatinib in adult patients with C-Kit positive acute myeloid leukemia.
    Kindler, T
    Breitenbuecher, F
    Marx, A
    Beck, J
    Hess, G
    Weinkauf, B
    Duyster, J
    Peschel, C
    Kirkpatrick, CJ
    Theobald, M
    Gschaidmeier, H
    Huber, C
    Fischer, T
    BLOOD, 2003, 102 (11) : 871A - 871A
  • [24] EXPRESSION OF ISOFORMS OF THE HUMAN RECEPTOR TYROSINE KINASE C-KIT IN LEUKEMIC-CELL LINES AND ACUTE MYELOID-LEUKEMIA
    CROSIER, PS
    RICCIARDI, ST
    HALL, LR
    VITAS, MR
    CLARK, SC
    CROSIER, KE
    BLOOD, 1993, 82 (04) : 1151 - 1158
  • [25] INCIDENCE AND PROGNOSTIC IMPACT OF C-KIT MUTATIONS IN PEDIATRIC CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA IN CHINA
    Wu, J.
    Zhang, L.
    Lu, A.
    Qin, Y.
    Wang, B.
    Cheng, Y.
    Liu, G.
    Chen, J.
    PEDIATRIC BLOOD & CANCER, 2013, 60 : 75 - 75
  • [26] Absence of mutations in the deoxycytidine kinase (dCK) gene in patients with relapsed and/or refractory acute myeloid leukemia (AML)
    van den Heuvel-Eibrink, MM
    Wiemer, EAC
    Kuijpers, M
    Pieters, R
    Sonneveld, P
    LEUKEMIA, 2001, 15 (05) : 855 - 856
  • [27] Absence of mutations in the deoxycytidine kinase (dCK) gene in patients with relapsed and/or refractory acute myeloid leukemia (AML)
    MM van den Heuvel-Eibrink
    EAC Wiemer
    M Kuijpers
    R Pieters
    P Sonneveld
    Leukemia, 2001, 15 : 855 - 856
  • [28] Clinical impact of c-KIT and CEBPA mutations in 33 patients with corebinding factor (Non-M3) acute myeloid leukemia
    Mao, Xiaoyan
    Yin, Runxiu
    Liu, Li
    Zhou, Yan
    Yang, Chunhui
    Fang, Chunlian
    Jiang, Hongchao
    Guo, Qulian
    Tian, Xin
    PEDIATRICS AND NEONATOLOGY, 2023, 64 (04): : 435 - 441
  • [29] Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)
    Boissel, N.
    Leroy, H.
    Brethon, B.
    Philippe, N.
    de Botton, S.
    Auvrignon, A.
    Raffoux, E.
    Leblanc, T.
    Thomas, X.
    Hermine, O.
    Quesnel, B.
    Baruchel, A.
    Leverger, G.
    Dombret, H.
    Preudhomme, C.
    LEUKEMIA, 2006, 20 (06) : 965 - 970
  • [30] Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)
    N Boissel
    H Leroy
    B Brethon
    N Philippe
    S de Botton
    A Auvrignon
    E Raffoux
    T Leblanc
    X Thomas
    O Hermine
    B Quesnel
    A Baruchel
    G Leverger
    H Dombret
    C Preudhomme
    Leukemia, 2006, 20 : 965 - 970